Cargando…
Hitherto unseen survival in an ALK‐positive‐patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine
Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologie...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715430/ https://www.ncbi.nlm.nih.gov/pubmed/29225862 http://dx.doi.org/10.1002/ccr3.1262 |